Tranzyme Exclusively Licenses Trans-Lentiviral Vector Technology to Open Biosystems | GenomeWeb

NEW YORK, Nov. 14 (GenomeWeb News) - Open Biosystems has obtained an exclusive license to use Tranzyme Pharma's trans-lentiviral gene-expression technology, the company said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.